~ Un-Common Sense In An Irrational World: We Challenge the Conventional WisdomTM ~
Trethera Seed Round Opportunity Webinar
Trethera’s $5M Seed Round closes soon — a limited opportunity to invest in a clinical-stage biotech advancing treatments for cancer and autoimmune diseases. Following its recent FDA Fast Track designation, investor interest is accelerating and below are key details for your consideration.
Key Details:
- Round closes September 30, 2025
- Minimum investment $50K
- Valuation $29.7M
Trethera is holding a webinar regarding this opportunity today, August 14th, at 1 pm Pacific Time. You can access the webinar at Invitation Link: https://us06web.zoom.us/webinar/register/7017551264754/WN_uGyv3wd6SXesum17RW9ohQ
You can access the complete webinar invitation on our Sponsored Research page for Trethera here.
About Trethera
Trethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera’s innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients.